Abstract:Objectives Dysregulated RNA alternative splicing is the hallmark of myotonic dystrophy type 1 (DM1). However, the association between RNA mis‐splicing and physical function in children with the most severe form of disease, congenital myotonic dystrophy (CDM), is unknown. Methods Eighty‐two participants (42 adults with DM1 and 40 children with CDM) with muscle biopsies and measures of myotonia, motor function, and strength were combined from five observational studies. Data were normalized and correlated with an aggregate measure of alternative splicing dysregulation, [MBNL]inferred, in skeletal muscle biopsies. Multiple linear regression analysis was performed to predict [MBNL]inferred using clinical outcome measures alone. Similar analyses were performed to predict 12‐month physical function using baseline metrics. Results Myotonia (measured via vHOT) was significantly correlated with RNA mis‐splicing in our cross‐sectional population of all DM1 individuals; CDM participants alone displayed no myotonia despite a similar range of RNA mis‐splicing. Measures of motor performance and muscle strength were significantly associated with [MBNL]inferred in our cohort of all DM1 individuals and when assessing children with CDM independently. Multiple linear regression analyses yielded two models capable of predicting [MBNL]inferred from select clinical outcome assessments alone in all subjects (adjusted R2 = 0.6723) or exclusively in children with CDM (adjusted R2 = 0.5875). Interpretation Our findings establish significant correlations between skeletal muscle performance and a composite measure of alternative splicing dysregulation, [MBNL]inferred, in DM1. The strength of these correlations and the development of predictive models will assist in designing efficacious clinical trials for individuals with DM1, particularly CDM.

Expression levels of core spliceosomal proteins modulate the MBNL-mediated spliceopathy in DM1

HNRNPA1-induced spliceopathy in a transgenic mouse model of myotonic dystrophy.

RNA mis-splicing in children with myotonic dystrophy is associated with physical function

Dose-Dependent Regulation of Alternative Splicing by MBNL Proteins Reveals Biomarkers for Myotonic Dystrophy

Alternative splicing of SORBS1 affects neuromuscular junction formation and stability in myotonic dystrophy type 1

RNA mis‐splicing in children with congenital myotonic dystrophy is associated with physical function

Treatment of Type 1 Myotonic Dystrophy by Engineering Site-specific RNA Endonucleases that Target (CUG)n Repeats

MBNL splicing factors regulate the microtranscriptome of skeletal muscles

Alternative splicing dysregulation across tissue and therapeutic approaches in a mouse model of myotonic dystrophy type 1

MBNL deficiency in motor neurons disrupts neuromuscular junction maintenance and gait coordination

The Splice Index as a prognostic biomarker of strength and function in myotonic dystrophy type 1

CUG repeat RNA-dependent proteasomal degradation of MBNL1 in a cellular model of myotonic dystrophy type 1

Combinatorial effects of ion channel mis-splicing as a cause of myopathy in myotonic dystrophy

A feedback loop regulates splicing of the spinal muscular atrophy-modifying gene, SMN2

Muscleblind-like 2 knockout shifts adducin 1 isoform expression and alters dendritic spine dynamics of cortical neurons during brain development

Reversal of RNA toxicity in myotonic dystrophy via a decoy RNA-binding protein with high affinity for expanded CUG repeats

Studying the Effect of MBNL1 and MBNL2 Loss in Skeletal Muscle Regeneration

Splice modulators target PMS1 to reduce somatic expansion of the Huntington’s disease-associated CAG repeat

SMN Deficiency Causes Tissue-Specific Perturbations in the Repertoire of snRNAs and Widespread Defects in Splicing

Mice lacking MBNL1 and MBNL2 exhibit sudden cardiac death and molecular signatures recapitulating myotonic dystrophy

Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers